Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Newborn Baby Screening for Fragile X Syndrome

Published: Thursday, January 03, 2013
Last Updated: Thursday, January 03, 2013
Bookmark and Share
Study for FXS demonstrates testing for mutations in the gene FMR1.

A study into newborn screening for fragile X syndrome (FXS) demonstrates that testing for mutations in the gene FMR1 can be done on a large scale.

The research, published in BioMed Central's open access journal Genome Medicine, shows that the number of carrier babies who carry the form of the gene known as the 'premutation' is higher than previously estimated.

Three large hospitals in the USA participated in this study, testing more than 14,000 newborns, including children of different ethnic backgrounds.

While only one child was identified with the full mutation, the team led by Dr Flora Tassone from UC Davis found that the prevalence of the premutation was higher than previously suggested, particularly for males (one in 209 females and one in 430 males).

Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability and autism, or autism spectrum disorder, and is caused by mutations in the gene FMR1.

The mutation which causes FXS is not actually in the gene but is due to the addition of extra CGG repeats in the promoter region that controls whether the gene is switched on or off.

The full mutation of more than 200 CGG repeats prevents proper functioning of the gene and causes FXS, while premutation (55 to 200 repeats) means that the baby has a higher chance of having a child with FXS, and has an increased risk child and adult-onset disorders such as neurological complications.

The impact of so called 'grey zone allele' (45 to 54 repeats) on health is currently not as clear, and is the focus of ongoing research.

However, the team also found that the Caucasian group had a higher prevalence of grey zone alleles than the Hispanic and African American groups.

Dr Tassone from UC Davis who led this study explains, "Our study shows that screening newborns for FXS can be done, but we will also identify carrier and grey zone babies as well as those with a full mutation. Before newborn screening for fragile X mutations is expanded nationally, we need to better understand the impact that identification of the premutation and grey zone allele has on families and systems will need to be in place to address the counseling and educational needs that inevitably will arise."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A Possible Blood Test for Alzheimer’s Disease
A new blood test can be used to discriminate between people with Alzheimer's disease and healthy controls.
Monday, July 29, 2013
Gene Signature Can Predict Who Will Survive Chemotherapy
An eight gene ‘signature’ can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central’s open access journal BMC Medicine.
Tuesday, April 16, 2013
Finding the Silent Killer – A Biomarker Test for Atherosclerosis
New research published in the journal BMC Medical Genomics has identified a set of biomarkers which can be used to test for early stage atherosclerosis.
Wednesday, January 11, 2012
Biomarker MIA Shows Presence of Neurofibromas
A simple blood test for the protein melanoma-inhibitory activity used to indicate the presence of neurofibromas even if they cannot be seen.
Tuesday, July 05, 2011
High Throughput RNAi Assay Optimization Using Adherent Cell Cytometry
Researchers from Harvard Medical School have detailed how adherent cell cytometry can be used as a high throughput-screening tool for the optimization of RNAi assays, accelerating in vitro cell assays and reducing costs.
Tuesday, May 03, 2011
Periodontal Treatment Effects on Endothelial Function and Cardiovascular Disease Biomarkers in Subjects with Chronic Periodontitis: Protocol for a Randomized Clinical Trial
Periodontal disease (PD) is an infectious clinical entity characterized by the destruction of supporting tissues of the teeth as the result of a chronic inflammatory response in a susceptible host. A study in the journal Trials evaluates if periodontal treatment with scaling and root planning supplemented with chlorhexidine improves endothelial function and other biomarkers of cardiovascular disease in subjects with moderate to severe periodontitis.
Thursday, February 17, 2011
Screensaver: An open Source Lab Information Management System (LIMS) for High-Throughput Screening Facilities
An Article published in BMC Bioinformatics details how researchers at Harvard Medical School’s Screening Facility and Department of Systems biology have developed Screensaver, a free, open source, web-based laboratory information management system (LIMS), to address the informatics needs of their small molecule and RNAi screening facility.
Monday, December 06, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos